Recent News

• 04.23.2025 - LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
• 12.19.2024 - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
• 12.13.2024 - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
• 12.13.2024 - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
• 11.07.2024 - LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
• 11.07.2024 - LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
• 11.07.2024 - LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
• 10.29.2024 - LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 10.25.2024 - LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

Recent Filings

• 03.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.14.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.19.2024 - EX-99.1 EX-99.1
• 12.19.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.12.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.12.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.07.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.01.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]